GLP-1 agonists: Difference between revisions

(Created page with "==Background== * Synthetic glucagon-like peptide-1 (GLP-1) receptor agonists * Stimulate insulin release from pancreatic islet cells ==Types== {| class="wikitable" |- ! Short...")
 
(internal link added)
Line 30: Line 30:


==See Also==
==See Also==
[[Diabetic medications]]
[[Diabetes medications]]


==References==
==References==

Revision as of 02:40, 23 August 2016

Background

  • Synthetic glucagon-like peptide-1 (GLP-1) receptor agonists
  • Stimulate insulin release from pancreatic islet cells

Types

Short Acting Dose
Exenatide(Byetta) 5-10 mcg SC bid
Liraglutide(Victoza) 0.6-1.8 mg SC daily
Long Acting
Exenatide(Bydureon) 2 mg SC qwk
Albiglutide(Tanzeum) 30-50 mg SC qwk
Dulaglutide(Trulicity) 0.75-1.5 mg qwk

Indication

  • Diabetes Mellitus, Type 2

Adverse Reactions

  • Nausea, vomiting, diarrhea
  • Acute pancreatitis
  • Exenatide should not be used in patients with creatinine clearance below 30mL/min
  • Should not be used if personal of family history of medullary thyroid cancer or MEN 2A/2B

See Also

Diabetes medications

References

1.Epocrates

2.http://www.uptodate.com/contents/glucagon-like-peptide-1-receptor-agonists-for-the-treatment-of-type-2-diabetes-mellitus?source=see_link&sectionName=GLUCAGON-LIKE+PEPTIDE-1&anchor=H2#H619400

Retrieved from "https://www.wikem.org/w/index.php?title=GLP-1_agonists&oldid=96215"